Skip to main content
OSCROscar Health, Inc.Hold6.6·$27.89
OSCR · Why this verdict

Why Oscar Health (OSCR) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score6.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Oscar Health is posting impressive 53% revenue growth and is the industry growth leader in healthcare plans, but 93% revenue concentration in government premium payments creates existential policy risk, and business quality at 2.9 remains well below the 4.0 investability floor.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

Quality scored 2.9 against a 4.0 minimum threshold, driven by very low return on assets, near-zero net margin, and a Piotroski F-Score of 6/9, placing the company below the quality floor for standard position eligibility.

Improving
Quality breakdown
Expectation
Quality score rises above 4.0 as operating margin expands above 5% and net margin turns consistently positive within 12 months.

CounterHealthcare plan operators run at thin margins by design; the appropriate comparison is the medical loss ratio trajectory, not absolute margin levels versus non-insurance peers.

Oscar Health delivered 53% year-over-year revenue growth, placing it as the industry growth leader in healthcare plans, reflecting successful member enrollment expansion.

Deteriorating
Growth breakdown
Expectation
Revenue growth remains above 20% for at least 2 consecutive quarters over the next 12 months.

CounterRevenue growth at this rate in government-sponsored insurance markets is heavily dependent on CMS rate increases and enrollment subsidies that can be reduced by policy changes.

CMS premiums account for 93% of all revenue, creating a single-source concentration risk where any reduction in CMS reimbursement rates, enrollment subsidies, or marketplace participation rules could substantially impair the business model.

Stable
Bear case
Expectation
Revenue diversification improves such that government-payer concentration falls below 85% within 24 months.

CounterSpecialist government health plan operators can earn strong returns precisely because they build deep operational expertise in navigating CMS regulations that generalist insurers lack.

The company produced a massive 88% earnings beat in the most recent quarter followed by a 35% miss the quarter prior, indicating high earnings unpredictability that makes forward planning unreliable.

Improving
Earnings
Expectation
Earnings surprise standard deviation narrows with 3 consecutive quarters of surprise within plus or minus 15% of estimates.

CounterThe recent 88% earnings beat ($2.07 vs $1.10 estimate) reflects genuine operational improvement in medical loss ratios that may be the inflection point the market is awaiting.

Per-dimension breakdown

Value

7.6/10data confidence 100%
ComponentSub-score
P/E6.1
P/S10.0
EV/EBITDA10.0
Fwd P/E7.6
PEG10.0
Analyst target3.0
  • Forward P/E: 16.3x
  • PEG: 0.13
  • Attractively valued

Quality

5.2/10data confidence 100%
ComponentSub-score
ROE10.0
ROA3.0
Gross margin0.0
Op margin3.2
Net margin1.8
Current ratio4.2
FCF quality9.2
Moat7.5
Piotroski F7.8
  • Excellent ROE: 34%
  • Excellent cash conversion: 126% FCF/NI
  • Wide economic moat
  • Compounder quality: strong returns + growth

Growth

9.2/10data confidence 67%
ComponentSub-score
Rev growth10.0
EPS growth8.4
  • Strong growth: 70% YoY

Momentum

4.8/10data confidence 100%
ComponentSub-score
RSI5.5
MACD0.0
OBV1.0
MA position4.0
Volume10.0
vol acceleration8.1
  • Volume distribution (falling OBV)
  • Above 200-day MA
  • Volume surge (2.0x avg) on up move

Sentiment

5.6/10data confidence 100%
ComponentSub-score
LLM sentiment7.1
Analyst rating5.0
Price target4.8
  • LLM news sentiment: +0.42 (n=5)

Insider

5.2/10data confidence 100%
ComponentSub-score
materiality2.0
insider conviction2.0
holder change10.0
notable moves7.0
  • Heavy insider selling — $74,471,326 (0.865% of mkt cap)
  • Institutions accumulating

Peer rank

7.7/10data confidence 80%
ComponentSub-score
value rank4.9
quality rank8.6
growth rank9.1
  • Superior ROE vs peers
  • Best-in-class margins

Technical

7.3/10data confidence 100%
ComponentSub-score
bollinger8.5
support resistance6.4
52w position6.9

Risk (lower is worse)

4.8/10data confidence 100%
ComponentSub-score
short interest6.0
days to cover7.4
volatility0.0
put call7.2
implied vol0.0
max pain risk7.0
beta2.1
debt equity9.1
  • High IV: 80%
  • Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

6.9/10data confidence 100%
ComponentSub-score
erm5.0
earnings history6.7
earnings timing5.0
surprise avg10.0
news activity8.0
  • Strong earnings: 3B/1M

How the verdict was assembled

Engine trigger

Maintain position. Not compelling to add more.

Engine technical detail
verdict_path: L4:PATH_F_HOLD
Passed (6)
  • MOMENTUM:4.8>=4.5
  • NEWS_BOOST:EARNINGS:0.60
  • NEWS_BOOST:ANALYST:0.50
  • EARNINGS_PROXIMITY:91d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (3)
  • ASYMMETRY:-1.1=NEGATIVE
  • INSIDER:0.86%=HEAVY
  • HEALTHCARE_GOV_PAYER:HARD_BLOCK
Warning (2)
  • MOMENTUM:4.8<5.5 (soft — BUY_NOW allowed but watch)
  • 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-1.06
Upside
-13.9%
Downside
13.1%
Sizing output
AVOID

Setup No clear chart pattern; technical signals are mixed

EdgeNo clear edge No clear edge identified

SuitabilityAggressive Beta 2.38>1.3

Investment implication

None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:4.8>=4.5. Top dim: Growth at 9.2; weakest: Risk (lower is worse) at 4.8. No conviction either direction.

The strongest dimensions are Growth at 9.2, Peer rank at 7.7, and Value at 7.6; the weakest are Risk (lower is worse) at 4.8, Momentum at 4.8, and Insider at 5.2. The V9 engine flagged 3 failed gates with 2 warnings, producing an asymmetric reward-to-risk of -1.06 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Revenue Growth 53pct Leadership

    Trip ifRevenue growth falls below 10% for 2 consecutive quarters.

  • P2Government Payer Concentration 93pct

    Trip ifCMS reimbursement rates decline by more than 3% or enrollment subsidies are reduced by more than 20% in a policy change announcement.

  • P3Quality Floor Breach

    Trip ifOperating margin falls below 3% for 2 consecutive quarters after the most recent improvement.

  • P4Earnings Volatility Inconsistency

    Trip ifEarnings miss exceeds negative 30% for 2 of the next 4 quarters.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home Stocks OSCR Why this verdict